Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
University of British Columbia · The University of Texas Southwestern Medical Center · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
484
total citations
- FWCI
- 39.00
- Percentile
- 100%
- References
- 29
Citations per year
Authors
13Topics & keywords
Topics
Keywords
- Medicine
- Placebo
- Clinical endpoint
- Population
- Neuromyelitis optica
- Internal medicine
- Clinical trial
- Intention-to-treat analysis
UN Sustainable Development Goals
- Reduced inequalities
No related works found for this paper.
Funding
- NMNational Multiple Sclerosis Society
- BBayer
- NNovartis
- RRoche
- BBiogen
- POPatient-Centered Outcomes Research Institute
- TPTeva Pharmaceutical Industries
- GCGuthy-Jackson Charitable Foundation
- JBJapan Blood Products Organization
- MSMultiple Sclerosis Society of Canada
- MMedImmune
- OPOtsuka Pharmaceutical
- MTMitsubishi Tanabe Pharma Corporation
- NINational Institutes of Health
- GGenentech
- CPChugai Pharmaceutical
- BCBayer Canada